絞り込み

16554

広告

Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.

著者 Carlson JJ , Guzauskas GF , Chapman RH , Synnott PG , Liu S , Russo ET , Pearson SD , Brouwer ED , Ollendorf DA
J Manag Care Spec Pharm.2018 Jan ; 24(1):29-38.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (213view , 0users)

Full Text Sources

Medical

New 3-drug regimens have been developed and approved to treat multiple myeloma (MM). The absence of direct comparative data and the high cost of treatment support the need to assess the relative clinical and economic outcomes across all approved regimens.
PMID: 29290170 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード